Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Net Margin (2020 - 2025)

Apellis Pharmaceuticals has reported Net Margin over the past 6 years, most recently at 101.83% for Q4 2025.

  • Quarterly results put Net Margin at 101.83% for Q4 2025, down 9542.0% from a year ago — trailing twelve months through Dec 2025 was 12.18% (up 1024.0% YoY), and the annual figure for FY2025 was 12.18%, up 1024.0%.
  • Net Margin for Q4 2025 was 101.83% at Apellis Pharmaceuticals, down from 47.04% in the prior quarter.
  • Over the last five years, Net Margin for APLS hit a ceiling of 1776.89% in Q4 2022 and a floor of 35183.15% in Q2 2021.
  • Median Net Margin over the past 5 years was 60.52% (2023), compared with a mean of 2111.88%.
  • Biggest five-year swings in Net Margin: surged 3422752bps in 2022 and later plummeted -183741bps in 2023.
  • Apellis Pharmaceuticals' Net Margin stood at 470.05% in 2021, then surged by 278bps to 1776.89% in 2022, then tumbled by -103bps to 60.52% in 2023, then skyrocketed by 89bps to 6.41% in 2024, then crashed by -1488bps to 101.83% in 2025.
  • The last three reported values for Net Margin were 101.83% (Q4 2025), 47.04% (Q3 2025), and 23.61% (Q2 2025) per Business Quant data.